Clinical Trial Update: A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of nintedanib for lymphangioleiomyomatosis (LAM) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: IRCCS Multimedica | Conditions: Lymphangioleiomyomatosis | Phase 2 | Status: COMPLETED